Making maternity care more accessible to all expectant parents including those in regional and rural Australians, HeraMED (ASX: HMD) has been promoting at-home pregnancy management using its digital monitoring device HeraCARE. Now the Company has levelled up its strategic shift for the device by securing a new Partner Agreement with Telstra Health, expanding its customer
Read More
Support is a fundamental need for all, but surprisingly lacking in most spheres of life. Pregnant women worldwide are often left to their own devices when it comes to navigating healthcare during pregnancy. Alone, they navigate the emotional and physical rollercoaster, with many Aussie women admitting to feeling distressed citing lack of support and knowledge.
Read More
Whilst the Government might be making (and subsequently reneging on) policy around prenatal care and IVF visits due to COVID, one company is actually making positive strides ahead. Medical data and technology company HeraMED (ASX: HMD) is readying themselves for a full commercial rollout of HeraCARE, their prenatal and foetal health monitoring system to expectant
Read More
With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote
Read More
Medical data and technology company HeraMED (ASX: HMD) has today announced a partnership to accelerate their mission to revolutionise maternal care. The Company has entered into a paid pilot with Obstetrix Medical Group, one of the largest clinical providers in the US for both women’s and children’s health. Obstetrix, an affiliate of US $2.2 billion
Read More
Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which
Read More